A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage.
BACKGROUND
Previous studies indicate that tazarotene is efficacious in reducing signs of photodamage. Objective We sought to confirm the efficacy and tolerability of tazarotene 0.1% cream in the treatment of facial photodamage.


METHODS
A total of 568 patients with at least moderate fine wrinkling or mottled hyperpigmentation applied tazarotene 0.1% cream or vehicle cream to their face once daily for 24 weeks.


RESULTS
Tazarotene cream was significantly more effective than vehicle in reducing fine wrinkles, mottled hyperpigmentation, lentigines, irregular depigmentation, apparent pore size, elastosis, tactile roughness, and an overall integrated assessment of photodamage. Significance was achieved as early as week 2 for some parameters and had not plateaued by week 24. The majority of patients reported improvements in their photodamage as early as week 4. Adverse events were predominantly mild or moderate signs or symptoms of skin irritation.


CONCLUSIONS
Once-daily tazarotene 0.1% cream is effective in ameliorating multiple signs of facial photodamage.
Kang
Sewon
S
University of Michigan Medical Center, Department of Dermatology, Ann Arbor, Michigan 48109-0314, USA. swkang@med.umich.edu
Krueger
Gerald G
GG
Tanghetti
Emil A
EA
Lew-Kaya
Deborah
D
Sefton
John
J
Walker
Patricia S
PS
Gibson
John R
JR
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005148:Facial Dermatoses / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D017495:Hyperpigmentation / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015595:Skin Aging / Q000187:drug effects*; D016896:Treatment Outcome; D014466:Ultraviolet Rays / Q000009:adverse effects*; D012176:Retinoids
D003879:Dermatologic Agents; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids